This site is intended for healthcare professionals

Phase III PRO2TECT study of Vafseo meets primary endpoints in anemia due to chronic kidney disease.- Akebia Therapeutics

Read time: 1 mins
Last updated:26th Oct 2020
Published:25th Oct 2020
Condition: Anaemia and CKD
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest